证券代码：600299 证券简称：安迪苏 公告编号：2025-027 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 召开的日期时间：2025 年 6 月 16 日 14 点 00 分 召开地点：北京市朝阳区北土城西路 9 号蓝星大厦会议室 (五)网络投票的系统、起止日期和投票时间。 蓝星安迪苏股份有限公司 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 16 日 至2025 年 6 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所上市公司自律监管指引第 1 号 ...

证券代码：600299 证券简称：安迪苏 公告编号：2025-027 蓝星安迪苏股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第二次临时股东大会 (二)股东大会召集人：董事会 网络投票系统：上海证券交易所股东大会网络投票系统 股东大会召开日期：2025年6月16日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 网络投票起止时间：自2025 年 6 月 16 日 至2025 年 6 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六)融资融券、转融 ...

强化财政支持。加大涉农专项资金统筹力度，推进先建后补、以奖代补。今年，省级安排现代农业发展 补助专项资金72亿元，重点支持高标准农田、区域性农业综合服务中心、秸秆综合利用等方面建设。各 地出台农业农村重点项目财政支持政策200余条。 强化金融支持。省农业农村厅每年联合人行江苏省分行印发农业农村重点项目对接清单，做好重点项目 融资对接。无锡市依托"乡村振兴金融联盟"平台，引导金融机构为27个重点项目放贷。镇江市开展"金 穗行动"，引导金融机构为40个重点项目授信。 强化用地保障。省农业农村厅连续两年会同省自然资源厅印发农业农村重点项目保障清单，为项目用地 提供优先保障。南通将农业农村重点项目用地保障写进市委一号文件，徐州则依托农业产业园区载体平 台，为项目落地建设创造有利条件。 广阔的市场空间、完备的产业配套、较强的科研实力、畅达的交通物流、一流的营商环境、得天独厚的 农业资源……江苏凭借综合实力成为企业投资兴业的"热土"。 □ 本报记者 吴 琼 小满时节，田间丰收在望，枝头杏肥梅黄。5月21日，一场以重点项目驱动乡村振兴的推进活动在南京 市溧水区火热开场——全省农业农村重点项目建设暨项目招引推进会重磅举行，国 ...

Core Points - The company announced a cash dividend distribution of 0.12 CNY per share (before tax) for the fiscal year 2024, totaling approximately 321.83 million CNY [1][4][5] - The dividend distribution plan was approved at the annual shareholders' meeting held on March 24, 2025 [1] - The key dates for the dividend distribution include the record date on May 19, 2025, the ex-dividend date on May 20, 2025, and the payment date also on May 20, 2025 [1] Dividend Distribution Details - The total number of shares for the dividend calculation is based on the company's total share capital of 2,681,901,273 shares [1] - The company will not issue bonus shares or increase capital through the dividend distribution [2] - The cash dividends will be distributed directly by the company to shareholders registered with the China Securities Depository and Clearing Corporation [2][4] Taxation Information - Individual shareholders holding shares for more than one year will be exempt from personal income tax on the dividend income [3] - For shares held for one month or less, the full dividend income will be subject to a 20% personal income tax [3] - For shares held between one month and one year, 50% of the dividend income will be included in taxable income, resulting in a 10% effective tax rate [3] Payment Process - The dividends for unrestricted circulating shares will be distributed through the clearing system of the China Securities Depository and Clearing Corporation [1][4] - The company will not withhold personal income tax at the time of dividend distribution; instead, the actual tax liability will be calculated based on the holding period [4] - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, resulting in a net dividend of 0.108 CNY per share [5]

证券代码：600299 证券简称：安迪苏 公告编号：2025-026 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 3 月 24 日的2024年年度股东大会审议通过。 二、 分配方案 蓝星安迪苏股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.12元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/5/19 | － | 2025/5/20 | 2025/5/20 | 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本2,681,901,273股为基数，每股派发现 金红利0.12元（含税），共计派 ...

Core Viewpoint - Andy Su, a leading global animal nutrition company, reported strong performance in Q1 2025, with significant revenue and profit growth driven by its dual pillar strategy focusing on methionine and specialty products [1][3]. Financial Performance - In Q1 2025, the company achieved revenue of 4.3 billion yuan, a year-on-year increase of 23% [1]. - Gross profit rose by 14% to 1.27 billion yuan, while net profit surged by 67.9% to 465 million yuan [1][3]. - The functional products segment generated revenue of 3.32 billion yuan, reflecting a 29% year-on-year growth, with methionine sales volume increasing by 24% [1][4]. Business Strategy - The company is implementing a "dual pillar" strategy to solidify its leadership in the methionine market while accelerating the development of specialty products [1][5]. - To meet global methionine demand, Andy Su plans to raise up to 3 billion yuan through a private placement to fund four core projects and enhance working capital [5][6]. Production Capacity and R&D Investment - The company is expanding its production capacity, with a new solid methionine project in Fujian province expected to produce 150,000 tons annually, set to commence operations in 2027 [5][6]. - R&D expenditures have been steadily increasing, totaling 1.858 billion yuan over the past five years, with a focus on green production, biotechnology, and digital services [2][6].

Investment Rating - The report maintains a "Strong Buy" rating for the company [2][5]. Core Views - The company reported a robust growth in Q1 2025, achieving a revenue of 4.299 billion yuan, a year-on-year increase of 22.98%, and a net profit of 465 million yuan, up 67.85% year-on-year [3]. - The core business segments showed strong performance, particularly the functional products segment, which saw a revenue increase of 29% to 3.319 billion yuan, driven by excellent performance in methionine and vitamin businesses [3]. - The company is expanding its methionine production capacity to solidify its leading position in the industry, with ongoing investments in its production platforms in Europe and Nanjing, China [4]. Financial Performance Summary - The company is projected to maintain its profit forecasts for 2025-2027, with net profits expected to be 1.637 billion yuan, 1.852 billion yuan, and 2.025 billion yuan respectively, corresponding to EPS of 0.61, 0.69, and 0.75 yuan [5][10]. - The current P/E ratios for 2025, 2026, and 2027 are projected to be 16, 14, and 13 times respectively [5]. Production Capacity Expansion - The company has two methionine production platforms, with a total annual capacity increase of 80,000 tons in Europe and 180,000 tons in Nanjing, China [4]. - A new solid methionine plant with an annual capacity of 150,000 tons is under construction in Quanzhou, expected to be operational by 2027 [4]. Market Position - The company is recognized as a leading player in the global animal nutrition industry and is the second-largest methionine producer worldwide, capable of producing both solid and liquid methionine [6].

Investment Rating - The investment rating for the company is "Outperform the Market" [3][5][18]. Core Views - The company's revenue and net profit for the first quarter of 2025 showed significant year-on-year and quarter-on-quarter growth, with revenue reaching 4.299 billion yuan, a year-on-year increase of 22.99% and a quarter-on-quarter increase of 3.38%. The net profit attributable to shareholders was 465 million yuan, up 67.85% year-on-year and 131.19% quarter-on-quarter [1][7]. - The growth in the company's methionine business, which saw a 29% year-on-year increase in sales revenue, was driven by a 24% increase in liquid methionine sales volume and price increases implemented during the quarter [2][10]. - The company is implementing a "dual pillar" strategy, with steady growth in specialty products, which saw a 7% increase in revenue and a 5% increase in gross profit [2][17]. Summary by Sections Financial Performance - In Q1 2025, the company's gross profit increased by 14% to 1.27 billion yuan, with functional product sales revenue growing by 29% and specialty product sales revenue increasing by 7% [1][7]. - The gross margin for sales was 29.64%, a year-on-year decrease of 2.32 percentage points but a quarter-on-quarter increase of 0.43 percentage points. The net profit margin was 10.82%, up 2.90 percentage points year-on-year and 5.96 percentage points quarter-on-quarter [1][7]. Business Segments - The methionine segment's sales revenue grew by 29% year-on-year, supported by price increases and high production capacity utilization, which mitigated the impact of rising raw material costs [2][10]. - The vitamin segment performed well, with strong sales growth despite price pressures on vitamin A and robust demand for vitamin E [2][15]. - Specialty products showed stable growth, with notable increases in sales from specific product lines, including a 21% increase in selenium products and a 24% increase in palatability products [2][17]. Profit Forecasts - The company is expected to achieve net profits of 1.625 billion yuan, 1.795 billion yuan, and 2.040 billion yuan for the years 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 35.0%, 10.4%, and 13.6% [3][18].

Summary of Key Points Core Viewpoint - As of April 29, 2024, a total of 5,105 companies have released their annual reports, with 2,456 companies reporting a year-on-year increase in net profit, while 2,649 companies reported a decline. Additionally, 2,890 companies saw an increase in operating revenue, and 2,214 companies experienced a decrease. Notably, 1,852 companies had both net profit and operating revenue growth, while 1,611 companies reported declines in both metrics. A total of 534 companies achieved a net profit growth rate exceeding 100%, with Zhengdan Co., Ltd. leading with a staggering increase of 11,949.39% [1]. Company Performance Highlights - Zhengdan Co., Ltd. reported earnings per share of 2.35 yuan, with a net profit of 1,189.89 million yuan, reflecting a year-on-year increase of 11,949.39%. The company's operating revenue reached 3,480.23 million yuan, up 126.31% [1]. - Guangxi Energy reported earnings per share of 0.043 yuan, with a net profit of 62.99 million yuan, showing a significant year-on-year increase of 3,704.04%. However, its operating revenue was 393,163.40 million yuan, down 76.48% [1]. - Siwei Technology achieved earnings per share of 0.98 yuan, with a net profit of 39.27 million yuan, marking a year-on-year increase of 2,662.76%. The operating revenue was 596,814.79 million yuan, up 108.87% [1]. - Other notable companies include Andis Su with a net profit of 1,204.33 million yuan (up 2,208.66%) and operating revenue of 1,553,427.50 million yuan (up 17.83%) [1]. Additional Company Insights - Petty Holdings reported a net profit of 182.21 million yuan, reflecting a year-on-year increase of 1,742.81%, with operating revenue of 165,904.03 million yuan, up 17.56% [1]. - The performance of ST Shengda showed a net profit of 11.99 million yuan, with a year-on-year increase of 1,190.67%, while its operating revenue was 73,254.96 million yuan, down 5.90% [1]. - Jiangsu Suopu reported a net profit of 21,274.20 million yuan, with a year-on-year increase of 1,029.62%, and operating revenue of 640,253.20 million yuan, up 18.43% [2].

蓝星安迪苏股份有限公司 公司《关于延长公司向特定对象发行 A 股股票股东大会决议有效期的议案》和 《关于提请股东大会延长授权董事会及其授权人士全权办理本次向特定对象发行 A 股 股票具体事宜的议案》尚需提交股东大会审议通过。 关于延长公司向特定对象发行 A 股股票股东大会决议有 效期及相关授权有效期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 蓝星安迪苏股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开公司第九届 董事会第六次会议、第九届监事会第五次会议，审议通过了《关于延长公司向特定对 象发行 A 股股票股东大会决议有效期的议案》和《关于提请股东大会延长授权董事会 及其授权人士全权办理本次向特定对象发行 A 股股票具体事宜的议案》。现将相关情 况公告如下： 公司于 2024 年 6 月 26 日召开 2023 年年度股东大会，审议通过了《公司向特定对 象发行 A 股股票预案》《提请股东大会授权董事会及其授权人士全权办理本次向特定 对象发行 A 股股票具体事宜的提案报告》等本次发行相关议案。根据上 ...